Sign inJoin waitlistJoin the waitlist

MN

Misako Nagasaka

Associate Professor — Division of Hematology and Oncology, Medicine · University of California

Credentials: · · · · · · ·

History

University of California
Present

Hematology and Medical Oncology
2014–2017
Internal Medicine
Icahn School of Medicine at Mount Sinai
2011–2014
St. Marianna University School of Medicine
2004–2008

Research

Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2022 · 868 citations
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2024 · 213 citations
Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer
Review · Expert Review of Anticancer Therapy · 2018 · First of 2 authors · 201 citations

SO
Sai-Hong I Ou
66 papers
AS
Ammar Sukari
35 papers
Zhaohui Arter
17 papers · 13 as a fellow
DB
Danielle Brazel
16 papers · 16 as a resident
Stephen Liu
16 papers
VZ
Viola Zhu
14 papers
MH
Mohammed Al Hallak
13 papers
SZ
Shannon Zhang
12 papers · 12 as a resident
Chul Kim
11 papers
AW
Antoinette Wozniak
10 papers
Jeremy Harris
10 papers
Jorge Nieva
10 papers

Clinical trials

Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects
Principal investigator · Recruiting
University of California, Irvine
2024–2026
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Site PI · Recruiting · Phase 3
Nuvalent Inc.
2025–2029
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Site PI · Recruiting · Phase 1, Phase 2
Nuvalent Inc.
2022–2028
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Site PI · Recruiting · Phase 1, Phase 2
Nuvalent Inc.
2022–2028